Pancreatic Cancer is a vicious killer. It is the fourth leading cause of cancer death, claiming a higher percentage of lives than any other form of cancer. More than 37,000 people in the U.S. are diagnosed with pancreatic cancer each year and 90% of them die from it. Men are diagnosed with pancreatic cancer slightly more often than women.
Pancreatic cancer has the worst five-year survival rate of any cancer, partly because the cancer has usually developed into a late-stage disease by the time it is diagnosed. Although smoking, diet, and diabetes all play a role in the development of pancreatic cancer, evidence suggests that genetics have a significant impact on pancreatic cancer. Genetic mutations that are passed on through families are the cause of 10 percent of the cases of pancreatic cancer. In addition, certain cancer-causing genes have been associated with pancreatic cancer.
Dr. Daniel Von Hoff leads the Clinical Translational Research Division at TGen. His team focuses on genetic and biochemical approaches to identify diagnostics and molecular targets for the development of new therapies for pancreatic cancer.
Dr. Daniel Von Hoff, M.D., F.A.C.P.,
Director of TGen's Clinical Translational Research Division
Dr. Von Hoff is world renowned for his contributions to pancreatic cancer research in addition to the development of new cancer drugs. Dr. Von Hoff and his team were instrumental in the development of one anti-cancer agent (gemcitabine) that significantly improves survival rates of patients with pancreatic cancer.
TGen's efforts in pancreatic cancer research are aided by the fact that Dr. Von Hoff has coordinated the formation of a world-wide team of experts solely focused on pancreatic research, named the Pancreatic Cancer Research Team (PCRT). Scientists within the PCRT share knowledge and resources to make rapid advances in pancreatic research. PCRT specializes in using this knowledge to initiate clinical trials to allow patients immediate access to newly developed therapies.
Mr. Marlon Somberg
Pancreatic Cancer Survivor
"I am living proof that pancreatic cancer can be defeated. The research undertaken by TGen's Dr. Von Hoff and the Pancreatic Cancer Research Team will continue to have a positive impact on others afflicted with this terrible disease."
Video - Advancing Pancreatic Cancer Research
The Pancreatic Cancer Research Team
Dr. Daniel Von Hoff
Your donation in support of Pancreatic Cancer research at TGen is important to furthering the institute's mission to develop earlier diagnoses and smarter treatments for patients.
Volunteer! Become a TGen Ambassador and help raise funds in your community for Pancreatic Cancer research.
To discuss ways to become involved and support cancer research at TGen, contact the TGen Foundation at Foundation@tgen.org, or call 602.343.8411.